Biotech Values

[marthambles]

All we know for sure is that "endpoints associated with male sexuality were mutually determined not to be appropriate as clinical endpoints". The only other endpoints available are T and endocrine. Since they are going with endocrine, it is logical to conclude that the FDA would not go along with T. I assume that this was their Plan B. It might be better than Plan A.